MitoRx Therapeutics Pre-Seed
mitorxtherapeutics.com
Cardiometabolic Therapeutics
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Latest round
Venture round
Dec 2025 · 10 mo ago
Backers
2
Future Planet Capital, Oxford Technology
The money's age
Fresh money
10 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 18, 2025
Raised a round Venture round
Dec 16, 2024
Raised a round Venture round
Jun 14, 2024
Raised a round Venture round
Oct 30, 2023
Raised a round Venture round
Mar 31, 2023
Raised a round Venture round
Mar 4, 2022
Raised a round Venture round
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Dec 2025 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Dec 2024 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Jun 2024 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Oct 2023 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Mar 2023 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Mar 2022 | — | — | find-and-update.company-information.service.gov.uk |
Registers and programsofficial lists and records that name the company
| Legal entity | MitoRx Therapeutics Limited | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Future Planet Capital 
Oxford Technology Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Refoxy Pharmaceuticals GmbH is a pre-clinical biotech company developing FOXO3-targeting therapies to restore cellular balance and treat…
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related…
Kailera is a late clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies to provide options for people…
Support gut health, reduce bloating, and feel fuller longer with Supergut’s 2:1 fiber blends. Delicious, easy daily nutrition for better…
Fight obesity within 20 minutes - fast, effective, long-term. A new weight-loss therapy for the treatment of obesity. Just a view minutes…
Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular…
News
MitoRx Therapeutics presents new preclinical data on MTRX31, demonstrating restored mitochondrial density, at the 62nd EASD Annual Meeting
MTRX31 shown to restore mitochondrial density in the liver of diet-induced obesity (DIO) mice to levels comparable to lean control mice MTRX31 also reduced lipid droplets and increased glycogen flexibility: evidence of repaired metabolic flexibility Harwe
Read more
Report
MitoRx Therapeutics to present new data on MTRX31, its novel mitochondrial-targeted small molecule, at the 62nd EASD Annual Meeting 2026
Oral presentation on durable and better quality weight loss induced by MTRX31 in an industry-standard preclinical model of obesity, with new data detailing its differentiated mode of action Structural biology and other data point to a single, unique, well
Read more
Report
MitoRx Therapeutics Appoints Clinical & Scientific Advisory Board to Guide the Development of MTRX31
Chaired by Mo Qatanani, PhD, Clinical & Scientific Advisory Board brings deep expertise in obesity, cardiometabolic disease and drug development Board will guide MitoRx's development strategy for lead asset MTRX31 as it advances towards the clinic for the
Read more
Report
MitoRx adds Babraham in Cambridge to its Oxford obesity drug capability - Business Weekly
Read article: https://www.businessweekly.co.uk/posts/mitorx-adds-babraham-in-cambridge-to-its-oxford-obesity-drug-capability The post MitoRx adds Babraham in Cambridge to its Oxford obesity drug capability - Business Weekly appeared first on MitoRx.
Read more
Report
Companies to Watch 2026: Seven innovators shaping next-generation obesity therapies - Clarivate
Read article: https://clarivate.com/life-sciences-healthcare/lp/companies-to-watch-2026-seven-innovators-shaping-next-generation-obesity-therapies/ The post Companies to Watch 2026: Seven innovators shaping next-generation obesity therapies - Clarivate ap
Read more
Report
MTRX31 restores mitochondrial metabolism in obesity - BioWorld
Read article: https://www.bioworld.com/articles/731840-mtrx-31-restores-mitochondrial-metabolism-in-obesity?v=preview The post MTRX31 restores mitochondrial metabolism in obesity - BioWorld appeared first on MitoRx.
Read more
Report
MitoRx's new obesity drug targets metabolism, not appetite - Longevity Technology
Read article: https://longevity.technology/news/mitorxs-new-obesity-drug-targets-metabolism-not-appetite/ The post MitoRx's new obesity drug targets metabolism, not appetite - Longevity Technology appeared first on MitoRx.
Read more
Report
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth
Alison Strutt appointed as Chief Financial Officer, László Tankó appointed as Consultant Chief Medical Officer, and Sam Fazeli appointed Non-Executive Director Appointments support MitoRx's next phase of growth as the Company advances MTRX31 for metabolic
Read more
Report
MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association's 2026 Scientific Sessions
MTRX31 led to a highly significant decrease in fat mass after two-months chronic dosing in a preclinical diet-induced obesity mouse model performed at thermoneutrality: Weight loss and reduction of fat deposits in multiple organs (ectopic fat) was observe
Read more
Report
Sachs 2nd Annual Obesity and Cardiometabolic Innovation Forum, June 5
Event: Sachs 2nd Annual Obesity and Cardiometabolic Innovation Forum Date: June 5, 2026 Location: Cologne, Germany Format: Panel Participation and Presentation The post Sachs 2nd Annual Obesity and Cardiometabolic Innovation Forum, June 5 appeared first o
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Oxford
United Kingdom
HQ
9400 Garsington Road, Oxford Business Park Oxford OX4 2HN, UK
Financials
Latest round
Venture - Series Unknown
Funding rounds
6